Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma
China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
From Reference Tool to Operating Model: A Roadmap for China’s C-List
China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
NFRA’s Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
NFRA’s latest Guiding Opinions signal a shift toward a more innovation-friendly commercial health insurance ecosystem. The article unpacks five key policy themes with critical implications for the C-List rollout and the building of China’s multi-level coverage framework.
Winning in China in a Multi-Level Coverage Era for Global Pharma
Success in China’s multi-level coverage era will hinge on three imperatives that upend old models and open new pathways.
▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog
What will China’s new dual-list mechanism mean for launch timing, pricing risks, and long-term market potential for innovative drugs?
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List
The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China
This Q&A explores the growing gap between global pharma strategies and China’s payer priorities—offering a self-assessment tool for internal alignment, and insights into risks and opportunities in the commercial catalog pathway.
